GETI.B

212.1

0%↓

BIOAB

319.6

+1.91%↑

EKTA.B

56.25

-0.35%↓

VITR

132.8

+3.51%↑

AMBEA

141.5

+1.51%↑

GETI.B

212.1

0%↓

BIOAB

319.6

+1.91%↑

EKTA.B

56.25

-0.35%↓

VITR

132.8

+3.51%↑

AMBEA

141.5

+1.51%↑

GETI.B

212.1

0%↓

BIOAB

319.6

+1.91%↑

EKTA.B

56.25

-0.35%↓

VITR

132.8

+3.51%↑

AMBEA

141.5

+1.51%↑

GETI.B

212.1

0%↓

BIOAB

319.6

+1.91%↑

EKTA.B

56.25

-0.35%↓

VITR

132.8

+3.51%↑

AMBEA

141.5

+1.51%↑

GETI.B

212.1

0%↓

BIOAB

319.6

+1.91%↑

EKTA.B

56.25

-0.35%↓

VITR

132.8

+3.51%↑

AMBEA

141.5

+1.51%↑

Начало・Списък с акции・Camurus AB

Camurus AB

Затворен

608.5 2.87

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

606

Максимум

611

Ключови измерители
By Trading Economics
Приходи	-99M 193M
Продажби	-108M 567M
P/E Средно за сектора	46.937 76.798
EPS	3.19
Марж на печалбата	33.972
Служители	280
EBITDA	-62M 253M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	432M 37B
Предишно отваряне	605.63
Предишно затваряне	608.5

Camurus AB Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.12.2025 г., 17:29 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19.12.2025 г., 16:47 ч. UTC

Значими двигатели на пазара

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19.12.2025 г., 16:10 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

21.12.2025 г., 23:51 ч. UTC

Пазарно говорене

Oil Rises Amid Growing U.S.-Venezuela Tensions -- Market Talk

21.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

21.12.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

19.12.2025 г., 22:33 ч. UTC

Печалби

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19.12.2025 г., 22:19 ч. UTC

Печалби

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19.12.2025 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 21:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19.12.2025 г., 21:38 ч. UTC

Печалби

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19.12.2025 г., 21:00 ч. UTC

Пазарно говорене

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19.12.2025 г., 20:23 ч. UTC

Пазарно говорене

Oil Futures End Down Week on Up Note -- Market Talk

19.12.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19.12.2025 г., 18:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19.12.2025 г., 18:00 ч. UTC

Пазарно говорене

Печалби

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19.12.2025 г., 17:41 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19.12.2025 г., 17:24 ч. UTC

Пазарно говорене

Печалби

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

19.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

19.12.2025 г., 16:29 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19.12.2025 г., 16:20 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19.12.2025 г., 16:19 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19.12.2025 г., 16:18 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19.12.2025 г., 16:16 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.12.2025 г., 16:16 ч. UTC

Пазарно говорене

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19.12.2025 г., 16:05 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 16:04 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 15:37 ч. UTC

Пазарно говорене

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Camurus AB Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.